Inventiva S.A. (EPA:IVA)

Market Cap	981.91M +310.6%
Revenue (ttm)	16.97M -10.4%
Net Income	-311.07M
EPS	-3.53
Shares Out	191.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	406,707
Average Volume	592,168
Open	5.06
Previous Close	5.14
Day's Range	4.99 - 5.33
52-Week Range	2.20 - 6.20
Beta	0.77
RSI	56.69
Earnings Date	Mar 30, 2026

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-β, a pre-clinical program for th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 84
• Stock Exchange: Euronext Paris
• Ticker Symbol: IVA

Financial Performance

In 2024, Inventiva's revenue was 14.09 million, a decrease of -38.24% compared to the previous year's 22.82 million. Losses were -184.21 million, 66.8% more than in 2023.